Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T (2010) Engineering and characterization of the long acting glucagon like peptide-1analogue LY2189265, an Fc fusion protein
Figures and comparison tables of GLP-1RAs provide valuable insights into dosing frequency, main use, weight loss efficacy, and blood sugar control, assisting healthcare professionals and patients in choosing the most appropriate treatment based on therapeutic goals and individual needs
Individuals with a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 should not use Liraglutide
Four-pathway activation provides weight loss, metabolic improvement, and muscle pr
Studies in people using GLP-1 medications have not documented lasting effects on ovulation or fertility capacity